Skip to main content
. 2015 Aug 25;5:13524. doi: 10.1038/srep13524

Figure 6. Activation of epidermal growth factor receptor (EGFR)–c-Src signaling is required for simvastatin-induced increase in sEH phosphatase activity.

Figure 6

BAECs were treated with simvastatin (10 μM) for 0–120 min. Cellular lysates were IB with (a) anti-phospho-epidermal growth factor receptor (p-EGFR) and EGFR and (b) anti-phospho-c-Src and c-Src. (c) Western blot analysis of anti-phosphor-c-Src and c-Src levels in BAECs pretreated with AG1478 (1 μM, a EGFR inhibitor) for 2 h, then simvastatin (10 μM) for 0–120 min. (d) Phosphatase activity (PT) assay of cells pretreated with AG1478 (1 μM) or protein phosphatase 1 (PP1; 10 μM) or transfected with K298M (a c-Src dominant-negative mutant) for 48 h, then simvastatin for 30 min. Data are mean ± SEM from 5 independent experiments. *P < 0.05 vs. vehicle- or vector-treated cells, #P < 0.05 vs. simvastatin-treated alone cells.